The use of monoclonal antibodies, genetic engineering, and recombinant molecules have greatly affected the diagnostics and therapeutics of thrombotic disorders. Future diagnostics and therapeutics will use chimeric or bifunctional antibodies, DNA probes, and perhaps liposomes in order to improve sensitivity and therapeutic efficacy. These highly sensitive… (More)
Figures and Tables
Sorry, we couldn't extract any figures or tables for this paper.